Literature DB >> 6403080

Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.

C A Fulcher, J R Roberts, T S Zimmerman.   

Abstract

Factor VIII procoagulant protein (VIII:C) purified from commercial factor VIII concentrate contained multiple polypeptides ranging in mol wt from 79,000 to 188,000, all of which were removed from solution by a monoclonal anti-VIII:C antibody specific for a thrombin-sensitive epitope. In a time-course digest of the purified VIII:C using a trace amount of purified human alpha-thrombin, changes occurred in all VIII:C polypeptides during the activation and inactivation of VIII:C activity. The generation and destruction of a mol wt 92,000 polypeptide paralleled the increase and decrease in VIII:C activity, suggesting that this polypeptide represents an activated form. These results provide the basis for a working hypothesis for the mechanism of thrombin activation of VIII:C.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

Authors:  J Y Chang; D M Monroe; D W Stafford; K M Brinkhous; H R Roberts
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  In-process controls and characterization of recombinate antihemophilic factor (recombinant).

Authors:  M Griffith; H Kingdon; S L Liu; W Burkart
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

Review 3.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

4.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

5.  Hemophilia A due to mutations that create new N-glycosylation sites.

Authors:  A M Aly; M Higuchi; C K Kasper; H H Kazazian; S E Antonarakis; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

6.  Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

Authors:  R De Cristofaro; V De Filippis
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

7.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

Authors:  L O Andersson; N Forsman; K Huang; K Larsen; A Lundin; B Pavlu; H Sandberg; K Sewerin; J Smart
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

Review 8.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

Review 9.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

10.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

Authors:  C A Fulcher; S de Graaf Mahoney; J R Roberts; C K Kasper; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.